Trevi Therapeutics (TRVI) Operating Expenses (2018 - 2025)

Trevi Therapeutics has reported Operating Expenses for 8 years, with the latest figure at $10.2 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Expenses fell 16.52% year-over-year to $10.2 million; the trailing twelve-month figure through Mar 2026 stood at $37.9 million (down 4.44% YoY), and the FY2025 full-year result was $49.3 million, down 4.26% from the prior year.
• Operating Expenses for Q4 2025 stood at $10.2 million, down from $13.9 million in the prior quarter.
• The five-year high for Operating Expenses was $14.1 million in Q3 2024, with the low at $6.7 million in Q4 2022.
• Average Operating Expenses over 5 years is $9.8 million, with a median of $8.9 million recorded in 2023.
• Year-over-year, Operating Expenses dropped 19.53% in 2022 and soared 58.54% in 2024.
• Tracing TRVI's Operating Expenses over 5 years: stood at $8.3 million in 2021, then dropped by 19.53% to $6.7 million in 2022, then jumped by 34.19% to $8.9 million in 2023, then jumped by 37.05% to $12.2 million in 2024, then dropped by 16.52% to $10.2 million in 2025.
• The last three Operating Expenses figures came in at $10.2 million (Q4 2025), $13.9 million (Q3 2025), and $13.7 million (Q2 2025), per Business Quant data.

Peer Comparison